Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.

Visa andra versioner (1)

BACKGROUND: Contemporary screening for prostate cancer frequently identifies small volume, low-grade lesions. Some clinicians have advocated focal prostatic ablation as an alternative to more aggressive interventions to manage these lesions. To identify which patients might benefit from focal ablati...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän:	Catto, J, Robinson, M, Albertsen, P, Goepel, JR, Abbod, M, Linkens, D, Davis, M, Rosario, D, Warren, A, Varma, M, Griffiths, D, Grigor, K, Mayer, N, Oxley, J, Deshmukh, N, Lane, J, Metcalfe, C, Donovan, J, Neal, D, Hamdy, F
Materialtyp:	Journal article
Språk:	English
Publicerad:	2011

Liknande verk

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study
av: Catto, J, et al.
Publicerad: (2011)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
av: Rosario, D, et al.
Publicerad: (2008)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
av: Lane, J, et al.
Publicerad: (2004)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: The ProtecT three-arm RCT
av: Hamdy, FC, et al.
Publicerad: (2020)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
av: Collin, S, et al.
Publicerad: (2009)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
av: Burton, A, et al.
Publicerad: (2013)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
av: Hamdy, F, et al.
Publicerad: (2006)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT
av: Freddie C Hamdy, et al.
Publicerad: (2020-08-01)

Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.
av: Zuccolo, L, et al.
Publicerad: (2013)

Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study
av: Dimitropoulou, P, et al.
Publicerad: (2011)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.
av: Dimitropoulou, P, et al.
Publicerad: (2011)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
av: Rosario, D, et al.
Publicerad: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
av: Rosario, D, et al.
Publicerad: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
av: Rosario, D, et al.
Publicerad: (2012)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
av: Wade, J, et al.
Publicerad: (2015)

Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protecT randomised controlled trial according to treatment received
av: Neal, D, et al.
Publicerad: (2019)

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).
av: Mills, N, et al.
Publicerad: (2006)

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
av: J. Donovan, et al.
Publicerad: (2003-01-01)

The ProtecT trial: Analysis of the patient cohort, baseline risk stratification and disease progression
av: Young, GJ, et al.
Publicerad: (2020)

Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study.
av: Mills, N, et al.
Publicerad: (2003)

Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
av: Murad, A, et al.
Publicerad: (2011)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
av: Lane, J, et al.
Publicerad: (2010)

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
av: S. Sanghera, et al.
Publicerad: (2020-10-01)

Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression.
av: Catto, J, et al.
Publicerad: (2006)

Predictive modeling in cancer: where systems biology meets the stock market.
av: Abbod, M, et al.
Publicerad: (2009)

Comparative study of intelligent models for the prediction of bladder cancer progression.
av: Abbod, M, et al.
Publicerad: (2006)

Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial
av: Johnston, T, et al.
Publicerad: (2016)

Experiences and decision processes during PSA testing and prostate biopsy: A qualitative study
av: Avery, K, et al.
Publicerad: (2007)

Artificial intelligence for the prediction bladder cancer
av: Abbod, M, et al.
Publicerad: (2004)

ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING
av: Burton, A, et al.
Publicerad: (2011)

Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
av: Catto, J, et al.
Publicerad: (2009)

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
av: Donovan, J, et al.
Publicerad: (2003)

THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS OF TREATMENTS FOR CLINICALLY LOCALISED PROSTATE CANCER
av: Lane, J, et al.
Publicerad: (2009)

The protect trial - Evaluating the effectiveness of treatments for clinically localised prostate cancer and associated molecular and genetic epidemiology studies
av: Lane, J, et al.
Publicerad: (2007)

Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
av: Chris Metcalfe, et al.
Publicerad: (2020-09-01)

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
av: Lane, A, et al.
Publicerad: (2016)

Development of a prognostic marker panel in bladder cancer using aberrant promoter methylation
av: Catto, J, et al.
Publicerad: (2007)

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial.
av: Er, V, et al.
Publicerad: (2017)

Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks.
av: Catto, J, et al.
Publicerad: (2003)

Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
av: Avery, K, et al.
Publicerad: (2008)